Showing results (1-10 of 38) with videos related to
Sort By:
Pageof 4
Pharmacoeconomics|January 29, 2011
Cost effectiveness of treatments for inflammatory bowel diseaseKeith BodgerPharmacoeconomics|September 13, 2005
Economic implications of biological therapies for Crohn's disease: review of infliximabKeith BodgerExpert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Economic burden of inflammatory bowel disease: a UK perspectiveCarlvin Luces, Keith BodgerBiologics : Targets & Therapy|June 1, 2013
New and emerging treatments for ulcerative colitis: a focus on vedolizumabTamsin Gledhill, Keith BodgerJournal of Crohn'S & Colitis|November 1, 2016
Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New DataDaniela Bojic, Keith Bodger, Simon TravisEuropean Journal of Gastroenterology & Hepatology|January 29, 2009
Safer sedation practice may not translate into improvements in endoscopic outcomesSanchoy Sarkar, Katherine Bowering, Waqar Azim, et al.Journal of Evaluation in Clinical Practice|January 21, 2006
A comparison of multivariable regression models to analyse cost dataSusanna Dodd, Asish Bassi, Keith Bodger, et al.Gut|October 11, 2013
Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-control questionnaireKeith Bodger, Clare Ormerod, Daniela Shackcloth, et al.Alimentary Pharmacology & Therapeutics|March 5, 2019
Systematic review: outcomes and adverse events from randomised trials in Crohn's diseaseHeather Catt, Dyfrig Hughes, Jamie J Kirkham, et al.Pageof 4